Stock listing
Soligenix, Inc.
Selected listing: 0A6I · LSE · USD · GB
Soligenix, Inc. (LSE:0A6I), Health Technology. Latest release Jun 8, 2026: Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine.
- Ticker
- LSE:0A6I
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LSE
- Currency
- USD
About Soligenix, Inc.
The company focuses on developing products to address unmet medical needs, particularly in the areas of rare diseases and biodefense. Soligenix is committed to advancing its innovative therapies through clinical development and regulatory approval processes.
Latest news from Soligenix, Inc.
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
June 8, 2026
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
May 26, 2026
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
May 8, 2026
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
April 27, 2026
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
April 1, 2026
Research Soligenix, Inc.
Alternate listings
SNGX:NASDAQ
US · USD
Alternate listing for Soligenix, Inc.; the primary context on this page is 0A6I:LSE.
SNGX:BOATS
US · USD
Alternate listing for Soligenix, Inc.; the primary context on this page is 0A6I:LSE.
DOA0:GETTEX
DE · EUR
Alternate listing for Soligenix, Inc.; the primary context on this page is 0A6I:LSE.
DOA0:MUN
DE · EUR
Alternate listing for Soligenix, Inc.; the primary context on this page is 0A6I:LSE.